Kyntra Bio, Inc.
KYNBHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeKyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Valued at $29.3M, KYNB is a micro-cap name in its sector. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Market Cap
$29.3M
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-0.63
EPS (TTM)
$-13.69
EPS (Fwd)
$-11.44
ROE
—
ROA
-20.2%
Cash
$87.2M
Total Debt
$19.2M
Free CF
$27.3M
52W Change
-5.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $87.2M in cash comfortably exceeding the $19.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $27.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Revenue has pulled back from $140.7M (2022) to $6.4M (2025), a 95% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing KYNB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.